Analysts forecast that Halyard Health, Inc. (NYSE:HYH) will report earnings of $0.48 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Halyard Health’s earnings, with estimates ranging from $0.46 to $0.49. Halyard Health also posted earnings of $0.48 per share in the same quarter last year. The business is scheduled to issue its next earnings report on Wednesday, November 1st.

On average, analysts expect that Halyard Health will report full-year earnings of $1.97 per share for the current financial year, with EPS estimates ranging from $1.95 to $2.00. For the next fiscal year, analysts forecast that the business will report earnings of $2.10 per share, with EPS estimates ranging from $2.07 to $2.14. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Halyard Health.

Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.14. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The business had revenue of $399.20 million during the quarter, compared to analyst estimates of $399.16 million. During the same period in the prior year, the company earned $0.45 earnings per share. Halyard Health’s revenue was down .2% compared to the same quarter last year.

A number of brokerages have commented on HYH. TheStreet raised shares of Halyard Health from a “c” rating to a “b” rating in a research note on Thursday, June 22nd. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research note on Wednesday, July 12th. BidaskClub downgraded shares of Halyard Health from a “buy” rating to a “hold” rating in a research note on Saturday, July 8th. Deutsche Bank AG lifted their target price on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $42.25.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/09/zacks-analysts-anticipate-halyard-health-inc-hyh-will-announce-earnings-of-0-48-per-share.html.

Shares of Halyard Health (NYSE HYH) traded up 0.35% during trading on Friday, reaching $45.83. The company’s stock had a trading volume of 430,078 shares. Halyard Health has a one year low of $31.59 and a one year high of $46.15. The firm’s 50-day moving average price is $42.57 and its 200-day moving average price is $39.44. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of 44.07 and a beta of 1.76.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its stake in shares of Halyard Health by 6,362.1% in the 1st quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after acquiring an additional 5,847,442 shares during the period. Vanguard Group Inc. raised its stake in shares of Halyard Health by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after acquiring an additional 196,367 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Halyard Health by 19.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after acquiring an additional 507,893 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Halyard Health by 242.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after acquiring an additional 1,320,735 shares during the period. Finally, State Street Corp raised its stake in shares of Halyard Health by 7.5% in the 2nd quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock valued at $66,872,000 after acquiring an additional 119,154 shares during the period. 91.02% of the stock is currently owned by institutional investors.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Get a free copy of the Zacks research report on Halyard Health (HYH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.